ASXL1 and acute myeloid leukemia: In a murine model, sequential acquisition of ASXL1 and SRSF2 mutations recapitulated features of clonal hematopoiesis and induced progression to MDS/AML, highlighting the biological basis for the adverse clinical outcomes associated with these mutations [82].